Dyax Corp., a prominent biopharmaceutical company headquartered in the United States, has been at the forefront of developing innovative therapies since its founding in 1995. Specialising in the field of rare diseases, particularly in the treatment of hereditary angioedema, Dyax has made significant strides in advancing patient care through its unique product offerings. The company is renowned for its flagship product, Kalbitor, which provides rapid relief for acute attacks of hereditary angioedema. Dyax's commitment to research and development has positioned it as a leader in the biopharmaceutical industry, with a strong focus on utilising its proprietary technology platforms to discover and develop novel therapeutics. With a robust pipeline and a dedication to improving patient outcomes, Dyax Corp. continues to solidify its reputation as a key player in the biopharmaceutical landscape.
We don't have data for Dyax Corp., but we can show you information about their parent organization instead.
View parent company